CerRx Receives $1.1 Million NIH Grant for Cancer Study - MyHighPlains.com
CerRx, Inc. (CerRx) today [Thursday] announced that it has been awarded a non-diluting National Institute of Health (NIH) grant of $1.1M to support a Phase I study combining its two lead investigational compounds intravenous (IV) fenretinide and IV safingol. These drugs act together to specifically kill cancer cells by increasing certain toxic ‘ceramide’ waxes in cancer cells.
C. Patrick Reynolds, M.D., Ph.D., chief scientific officer of CerRx and director at the Texas Tech University Health Sciences Center (TTUHSC) School of Medicine Cancer Center, said, “The combination of fenretinide plus safingol provides a very exciting and novel approach to selectively attacking cancer cells of many types in adults and children and we are delighted that this imporant clinical trial will be carried out here in Texas.”
Read the full story >>
TTUHSC Celebration of Life Service was held March 25th in remembrance of Tom McGovern, Ed.D.
TTUHSC has been named as a Military Friendly® School for 2022-2023. Among graduate schools, TTUHSC ranked fourth in the nation, achieving Gold award status.
On March 16, fourth-year TTUHSC Jerry H. Hodge School of Pharmacy students interested in completing a residency after they graduate in May, learned where they would spend the next stage of their training during the Pharmacy Residency Match Day.
The Innovation Hub at Research Park today (September 26, 2022) announced the winners of its annual Presidents' Innovative Startup Awards. The award recognizes startups that have a high potential for growth and an economic impact in West Texas.
Pablo Artigas, Ph.D., from TTHSC's School of Medicine’s Department of Cell Physiology and Molecular Biophysics, published a study with his team of collaborators in Nature Communications.